Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) EBITDA: 2016-2024

Historic EBITDA for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to -$220.8 million.

  • Autolus Therapeutics' EBITDA fell 54.13% to -$84.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$228.8 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of -$220.8 million for FY2024, which is 11.27% down from last year.
  • Latest data reveals that Autolus Therapeutics reported EBITDA of -$220.8 million as of FY2024, which was down 11.27% from -$198.5 million recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' EBITDA registered a high of -$144.8 million during FY2021, and its lowest value of -$220.8 million during FY2024.
  • In the last 3 years, Autolus Therapeutics' EBITDA had a median value of -$198.5 million in 2023 and averaged -$199.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first climbed by 2.83% in 2020, then dropped by 23.73% in 2022.
  • Yearly analysis of 5 years shows Autolus Therapeutics' EBITDA stood at -$145.2 million in 2020, then rose by 0.29% to -$144.8 million in 2021, then declined by 23.73% to -$179.2 million in 2022, then decreased by 10.78% to -$198.5 million in 2023, then dropped by 11.27% to -$220.8 million in 2024.